Real-World Evidence in mCRC: Special Populations and Safety Assessment

Panelists note that patients with ECOG performance status (PS) 2 are underrepresented in clinical trials, making real-world data especially critical in guiding their care.

They highlight how emerging real-world evidence (RWE) provides insight into outcomes and tolerability for these vulnerable populations, supplementing limited trial evidence.

In addition, they discuss how real-world safety signals—sometimes distinct from clinical trials—must be carefully considered when determining treatment sequencing and monitoring approaches.